Literature DB >> 16530894

A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan.

Takao Nagai1, Teruo Okafuji, Chiaki Miyazaki, Yuhei Ito, Makoto Kamada, Takuji Kumagai, Kenji Yuri, Hiroshi Sakiyama, Akiko Miyata, Toshiaki Ihara, Hitoshi Ochiai, Kunihisa Shimomura, Eitaro Suzuki, Sadayoshi Torigoe, Masahiro Igarashi, Tetsuo Kase, Yoshinobu Okuno, Tetsuo Nakayama.   

Abstract

To compare the incidence of aseptic meningitis associated with symptomatic natural mumps infection and in mumps vaccine recipients, we conducted a prospective comparative study. Consecutive samples of 1051 children with mumps were enrolled by 10 pediatricians and 21,465 vaccine recipients by 143 pediatric primary care practitioners, from January 1, 2000 to January 1, 2003. Parents used a daily diary to record symptoms during the period of illness (15 days) or 30-day period following immunization. Mumps infection was confirmed by virus isolation and/or detection of mumps virus genome in salivary and CSF samples. The incidence of aseptic meningitis was 13/1051 (1.24%) in patients with symptomatic natural mumps infection and was estimated to be 0.7-1.1% of overall infection in considering asymptomatic infection, and 10/21,465 (0.05%) in vaccine recipients. Although aseptic meningitis is a clear side effect of the mumps vaccine, the incidence is considerably lower than among those with symptomatic natural infection. Our results provide an informative data for consideration to resume mumps vaccine as a part of routine immunization schedule for Japanese children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530894     DOI: 10.1016/j.vaccine.2005.11.068

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Close the gap for routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

2.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

Review 3.  Molecular biology, pathogenesis and pathology of mumps virus.

Authors:  Steven Rubin; Michael Eckhaus; Linda J Rennick; Connor G G Bamford; W Paul Duprex
Journal:  J Pathol       Date:  2015-01       Impact factor: 7.996

4.  Mumps-Related Disease Burden in Japan: Analysis of JMDC Health Insurance Reimbursement Data for 2005-2017.

Authors:  Satoko Ohfuji; Akira Takagi; Takashi Nakano; Hideaki Kumihashi; Munehide Kano; Toshihiro Tanaka
Journal:  J Epidemiol       Date:  2021-01-13       Impact factor: 3.211

Review 5.  Vaccine chronicle in Japan.

Authors:  Tetsuo Nakayama
Journal:  J Infect Chemother       Date:  2013-07-09       Impact factor: 2.211

6.  History repeats itself in Japan: Failure to learn from rubella epidemic leads to failure to provide the HPV vaccine.

Authors:  Yusuke Tanaka; Yutaka Ueda; Kiyoshi Yoshino; Tadashi Kimura
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

7.  Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.

Authors:  Tetsuo Nakayama; Masahiro Eda; Motonori Hirano; Wakako Goto
Journal:  Hum Vaccin Immunother       Date:  2019-04-22       Impact factor: 3.452

8.  A new method for the detection of neutralizing antibodies against mumps virus.

Authors:  Keita Matsubara; Motoko Fujino; Kaoru Takeuchi; Satoshi Iwata; Tetsuo Nakayama
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.